SEC Comment Letter for CytomX Therapeutics, Inc. (CTMX) (CIK 0001501989) (CTMX) — Apr 29, 2020

CytomX Therapeutics, Inc. (CTMX) (CIK 0001501989)
Date: April 29, 2020 · CIK: 0001501989 · Accession: 0000000000-20-003688

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-37587

Date

April 29, 2020

Author

Lloyd Rowland, Esq.

Form

UPLOAD

Company

CytomX Therapeutics, Inc. (CTMX) (CIK 0001501989)

Letter

United States securities and exchange commission logo April 29, 2020 Lloyd Rowland, Esq. General Counsel CytomX Therapeutics, Inc. 151 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 Re:CytomX Therapeutics, Inc. Preliminary Proxy Materials on Schedule 14A Filed on April 17, 2020 File No. 001-37587 Dear Mr. Rowland: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mark Roeder, Esq.

Show Raw Text

United States securities and exchange commission logo
April 29, 2020
Lloyd Rowland, Esq.
General Counsel
CytomX Therapeutics, Inc.
151 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080
Re:CytomX Therapeutics, Inc.
Preliminary Proxy Materials on Schedule 14A
Filed on April 17, 2020
File No. 001-37587
Dear Mr. Rowland:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Mark Roeder, Esq.

SecProbe.io